← Back to Search

Genomic Analysis for Cancer

N/A

Recruiting

Led By Shridar Ganesan

Research Sponsored by Rutgers, The State University of New Jersey

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Paraffin blocks of the patient's tumor tissue are available and accessible for analysis

Karnofsky/Lansky performance score >= 30

Must not have

Karnofsky/Lansky performance score < 30

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 15 years

Awards & highlights

No Placebo-Only Group

Summary

This triallooks into using genomic sequencing to diagnose and treat cancer, potentially improving care for patients with rare, hard-to-treat cancers.

Who is the study for?

This trial is for patients with rare or hard-to-treat cancers who have a Karnofsky/Lansky score of at least 30, indicating they can care for themselves. They must have confirmed cancer diagnosis, available tumor tissue samples, and consent to participate. Those with life expectancy under 3 months or very poor physical condition (score below 30) cannot join.

What is being tested?

The study is examining the use of targeted genomic analysis on blood and tissue from cancer patients to identify genetic changes that could be important in cancer development. This may help improve diagnosis and treatment options for those with rare cancers that respond poorly to standard therapies.

What are the potential side effects?

Since this trial involves collecting samples and analyzing them in a lab rather than testing drugs, there are no direct side effects related to medications. However, the procedure might cause discomfort or complications like bleeding or infection at the collection site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My tumor tissue samples are available for testing.

Select...

I can care for myself but may need occasional help.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am unable to care for myself and spend all day in bed.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 15 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 15 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 15 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Frequencies of individual specific mutations and combinations of mutations of related pathway genes

Rate of actionable mutations in rare and/or poor prognosis cancers

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Ancillary-Correlative (genomic analysis)Experimental Treatment2 Interventions

Previously collected tissue samples are analyzed for the presence of mutations via next generation sequencing. Patients may also undergo collection of blood samples for analysis of circulating cell-free DNA and circulating tumor cells.

0 / 3Eligibility criteria met